A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn's Disease.
Ahmed M I ElfikyIshtu L HagemanMarte A J BeckerJan VerhoeffAndrew Y F Li YimVincent W JoustraLieven MuldersIvan FungInmaculada RiojaRab K PrinjhaNicholas N SmithersRebecca C FurzePalwinder K ManderMatthew J BellChristianne Johanna BuskensGeert R D'HaensManon E WildenbergWouter J de JongePublished in: Cells (2022)
We demonstrate specific CES1 expression in mononuclear myeloid cell subsets in peripheral blood and inflamed tissues of CD patients. We report that low dose ESM-iBET accumulates in CES1-expressing cells and exerts robust anti-inflammatory effects, which could be beneficial in refractory CD patients.
Keyphrases
- peripheral blood
- end stage renal disease
- low dose
- ejection fraction
- induced apoptosis
- newly diagnosed
- chronic kidney disease
- gene expression
- dendritic cells
- peritoneal dialysis
- poor prognosis
- bone marrow
- stem cells
- acute myeloid leukemia
- oxidative stress
- cell cycle arrest
- high dose
- patient reported outcomes
- signaling pathway
- binding protein
- long non coding rna